Joshua M. Korn

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Josh Korn, Joshua Korn, Joshua M Korn, Joshua Marc Korn
Publication record
72 papers · 27,258 citations · H-index 33

PAPERS

Generating a murine PTEN null cell line to discover the key role of p110β-PAK1 in Castration-Resistant Prostate Cancer invasion.
20231 citationsauthor #7
Expressed barcoding enables high resolution tracking of the evolution of drug tolerance.
20237 citationsauthor #24
Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.
20224 citationsauthor #11
Contribution and clinical relevance of germline variation to the cancer transcriptome
20221 citationsauthor #4
PISCES: a package for rapid quantitation and quality control of large scale mRNA-seq datasets
20204 citationsauthor #4
A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts
202014 citationsauthor #4
Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts
20200 citationsauthor #4
Abstract PO-100: Expressed molecular barcoding coupled with single cell RNAseq enables a high resolution investigation into the evolution of drug tolerance
20200 citationsauthor #12
Patient-derived glioblastoma cultures as a tool for small-molecule drug discovery
202018 citationsauthor #3
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
2019175 citationsauthor #17
Abstract A122: Molecular barcoding and single cell approaches to investigate drug tolerance in EGFRmutNSCLC
20190 citationsauthor #14
In-Depth Characterization and Validation in BRG1-Mutant Lung Cancers Define Novel Catalytic Inhibitors of SWI/SNF Chromatin Remodeling
20198 citationsauthor #24
Abstract 4769: Gene expression profiling of response to short- and long-term treatment of LSZ102 in MCF7 cells
20190 citationsauthor #2
Abstract 394:In vivoshRNA screens under treatment pressure by BRAF and MEK inhibitors to identify novel combination treatment strategies forBRAF-mutant colorectal cancer
20190 citationsauthor #11
Next-generation characterization of the Cancer Cell Line Encyclopedia
20192,680 citationsauthor #37
Abstract DDT01-04: Pharmacological profile and anti-tumor properties of LXH254, a highly selective RAF kinase inhibitor
20182 citationsauthor #9
Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss
2018284 citationsauthor #18
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
201829 citationsauthor #9
Correction of copy number induced false positives in CRISPR screens
201718 citationsauthor #4
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening.
2017578 citationsauthor #62
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity
201719 citationsauthor #10
Running Title : Characterizing BRAF Inhibitor-associated MEK Mutants Corresponding
20170 citationsauthor #10
CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions.
2016332 citationsauthor #5
Correction: Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages
20160 citationsauthor #6
ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor
201667 citationsauthor #2
Abstract 2692: High allele frequency of KRAS functional mutations predicts resistance to MEK inhibitors: Evidence from cell lines and human tumor xenograft models
20150 citationsauthor #4
Abstract 2847: High complexity barcoding to study clonal dynamics in response to cancer therapy
20150 citationsauthor #17
Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages
201514 citationsauthor #8
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
20151,198 citationsauthor #2
Abstract 3240: Understanding clonal complexity of a tumor xenograft model via cellular barcoding technology
20150 citationsauthor #7
Abstract B36: Modeling genetic mechanisms of resistance in melanoma primary tumor xenografts
20150 citationsauthor #3
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
2015460 citationsauthor #22
Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
2015129 citationsauthor #4
Inhibition of Casein Kinase 1 Alpha Prevents Acquired Drug Resistance to Erlotinib in EGFR-Mutant Non-Small Cell Lung Cancer.
201553 citationsauthor #8
Androgen receptor mutation
20140 citationsauthor #4
Therapeutics , Targets , and Chemical Biology Inhibiting Tankyrases Sensitizes KRAS-Mutant Cancer Cells to MEK Inhibitors via FGFR 2 Feedback Signaling
20140 citationsauthor #6
Inhibiting Tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling.
201440 citationsauthor #7
Abstract LB-107: Inhibiting TNKS sensitizes KRAS mutant cancer cells to MEK inhibitors by suppressing FGFR2 feedback signaling
20140 citationsauthor #8
TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation
201459 citationsauthor #4
Targeting HSF1 sensitizes cancer cells to HSP90 inhibition
201368 citationsauthor #8
Abstract C149: The PKC inhibitor Sotrastaurin selectively inhibits the growth of GNAQ mutant uveal melanoma.
20130 citationsauthor #6
An F 876 L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV 3100 ( Enzalutamide )
201336 citationsauthor #2
Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma
2013329 citationsauthor #4
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).
2013516 citationsauthor #2
Abstract A11: Modeling drug response and resistance using patient-derived xenograft models.
20130 citationsauthor #7
Isocitrate Dehydrogenase Mutations Promote a ZEB1/mir-200-dependent Epithelial Mesenchymal Transition
20120 citationsauthor #8
Efficiency and Power as a Function of Sequence Coverage, SNP Array Density, and Imputation
201229 citationsauthor #2
Isocitrate Dehydrogenase (IDH) Mutations Promote a Reversible ZEB1/MicroRNA (miR)-200-dependent Epithelial-Mesenchymal Transition (EMT)*
2012101 citationsauthor #12
Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease
2011801 citationsauthor #18
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers
201121 citationsauthor #7
The efficacy of detecting variants with small effects on the Affymetrix 6.0 platform using pooled DNA
20114 citationsauthor #3
Discovery and genotyping of genome structural polymorphism by sequencing on a population scale
2011358 citationsauthor #2
Family-based genetic risk prediction of multifactorial disease
201023 citationsauthor #2
Copy Number Variation in the Human Genome: Tools, Methods, and Applications to Disease
20100 citationsauthor #1
Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer
20104 citationsauthor #5
Accurately Assessing the Risk of Schizophrenia Conferred by Rare Copy-Number Variation Affecting Genes with Brain Function
2010167 citationsauthor #2
Mapping copy number variation by population scale genome sequencing
20101,119 citationsauthor #22
Rapid Assessment of Genetic Ancestry in Populations of Unknown Origin by Genome-Wide Genotyping of Pooled Samples
201049 citationsauthor #3
Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer
2010159 citationsauthor #5
Integrating common and rare genetic variation in diverse human populations
20103,019 citationsauthor #27
Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer
201018 citationsauthor #5
Consortium, G.P A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073
201014 citationsauthor #321
Abstract 1789: Genomic Analyses Identify New Loci and Genes in Isolated, Sporadic Congenital Heart Disease
20090 citationsauthor #14
De Novo Copy Number Variants Identify New Genes and Loci in Isolated, Sporadic Tetralogy of Fallot
2009432 citationsauthor #9
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants
20091,130 citationsauthor #63
Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs
2008836 citationsauthor #1
Integrated detection and population-genetic analysis of SNPs and copy number variation
2008995 citationsauthor #3
Association between microdeletion and microduplication at 16p11.2 and autism.
20081,596 citationsauthor #3
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
20086,902 citationsauthor #103
Mapping and sequencing of structural variation from eight human genomes
20081,213 citationsauthor #32
Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders
2008347 citationsauthor #4
The plasticity of dendritic cell responses to pathogens and their components.
2001792 citationsauthor #5

TIMELINE

2001 792 citations

2008 11,889 citations

2009 1,562 citations

2010 4,572 citations

2011 1,184 citations

2012 130 citations

2013 949 citations

2014 99 citations

2015 1,854 citations

2016 399 citations

2017 615 citations

2018 315 citations

2019 2,863 citations

2020 36 citations

2022 5 citations

2023 8 citations

COAUTHOR MAP

CONCEPT FOOTPRINT